Although the benefit of adjuvant cisplatin-based chemotherapy for patients with high-risk UTUC is still controversial [1,14,15], EV may be useful as an adjuvant therapy for patients with high-risk UTUC expressing high levels of Nectin-4. This evidence concerns the gene NECTIN4 and renal pelvis/ureter urothelial carcinoma.